Kepler Capital Sticks to Their Hold Rating for Qiagen (QGEN)

In a report released on November 8, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen (QGENResearch Report), with a price target of EUR50.00. The company’s shares closed yesterday at $44.50.

Pataki covers the Healthcare sector, focusing on stocks such as Qiagen, Tecan Group AG, and Demant. According to TipRanks, Pataki has an average return of -18.2% and a 29.56% success rate on recommended stocks.

In addition to Kepler Capital , Qiagen also received a Hold from UBS’s John Sourbeer in a report issued on November 8. However, yesterday, J.P. Morgan maintained a Buy rating on Qiagen (NYSE: QGEN).

See today’s best-performing stocks on TipRanks >>

QGEN market cap is currently $10.05B and has a P/E ratio of 19.89.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Read More on QGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More